Also trades as: TATVA.NS (NSE) · $vol 2M
TATVA.BO BSE
Tatva Chintan Pharma Chem Limited
1W: +0.9%
1M: +9.3%
3M: +40.1%
YTD: +46.0%
1Y: +63.7%
3Y: +4.9%
₹1,739.20 ($18.06)
-42.65 (-2.39%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$296M
+20.1% ▲
5Y CAGR: +8.5%
Capital Expenditures
$1.1B
-49.2% ▼
5Y CAGR: +40.2%
Free Cash Flow
-$841M
-63.1% ▼
Dividends Paid
$23M
+50.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$50M
+79.2% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $1.0B | $448M | $304M | $57M | $421M |
| Depreciation & Amort. | $82M | $96M | $256M | $277M | $368M |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$754M | -$284M | $357M | -$77M | -$619M |
| Other Non-Cash Items | -$166M | $19M | $64M | -$10M | $127M |
| Operating Cash Flow | $204M | $278M | $980M | $247M | $296M |
| — Investing Activities — | |||||
| Capital Expenditures | -$892M | -$2.0B | -$1.3B | -$763M | -$1.1B |
| Acquisitions (Net) | $780K | $680K | $0 | $1M | $4M |
| Investment Purchases | -$1.1B | -$967M | -$99M | $0 | -$87M |
| Investment Sales | $1.1B | $967M | $144M | $104M | $40M |
| Other Investing | -$1.1B | $1.0B | $34M | $5M | $14M |
| Investing Cash Flow | -$2.0B | -$1.0B | -$1.2B | -$653M | -$1.2B |
| — Financing Activities — | |||||
| Net Debt Issuance | $289M | $506M | -$1.5B | $225M | $840M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | -$44M | -$47M | -$47M | -$23M |
| Other Financing | -$50M | -$84M | $1.9B | -$13M | -$280K |
| Financing Cash Flow | $2.3B | $378M | $305M | $166M | $816M |
| Net Change in Cash | $585M | -$357M | $79M | -$239M | -$50M |
| Cash End of Period | $630M | $274M | $353M | $114M | $88M |
| Free Cash Flow | -$688M | -$1.8B | -$305M | -$516M | -$841M |